Benzinga | Aug 6, 2021 12:15PM EDT

Raymond James Maintains Outperform on Intellia Therapeutics, Raises Price Target to $181

Raymond James analyst Steven Seedhouse maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and raises the price target from $168 to $181.